After PACAP infusion, a delayed migraine-like headache was reported by 23 of 32 patients (72%) and 11 of those 23 (48%) reported one or more premonitory symptoms prior to the headache [38]. This evidence concerns the gene ADCYAP1 and migraine disorder.